Johnson & Johnson abandons 400 million euro TachoSil acquisition citing regulatory concerns
MLex Summary: Johnson & Johnson's unit Ethicon has abandoned its acquisition of TachoSil Fibrin Sealant Patch from Takeda Pharmaceuticals, citing regulatory concerns in a statement.Statement follows below:...To view the full article, register now.
Already a subscriber? Click here to view full article